ACD A- citric acid monohydrate, dextrose monohydrate, and trisodium citrate dihydrate injection, solution

ACD by

Drug Labeling and Warnings

ACD by is a Prescription medication manufactured, distributed, or labeled by Terumo BCT, Ltd.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is an anticoagulant for blood collection for use only with apheresis devices. [See Dosage and Administration (2).]

  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Dosing Information

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is added to tubing sets during apheresis procedures. The solution is connected to the tubing set in an apheresis collection. The recommended dose is determined by the apheresis device and metered into the tubing set by the apheresis device. It is not intended for direct intravenous infusion.

    For instructions on the use of the solution with the apheresis device and tubing set, see the device operator's manual.

    2.2 Administration

    • Ensure solution is the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A and is within the expiration date.
    • Inspect the bag. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration.
    • Use only if solution is clear and free of particulate matter.
    • Protect from sharp objects.

    Directions for Connecting the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A bag to the apheresis device.

    At the prompt to connect anticoagulant to the apheresis device tubing set:

    1. Remove the overwrap by pulling down at notch, and remove the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A bag.
    2. Before use, perform the following checks [See Warnings and Precautions (5).]:
      • Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
      • Ensure that the solution is the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A and is within the expiration date.
      • Inspect the solution in adequate light. Bags showing cloudiness, haze, or particulate matter should not be used.
    3. Remove the protective cap from the port on the bag.
    4. Connect the bag to the apheresis device tubing set using aseptic technique and hang the solution.
    5. Break the frangible connector. When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow.
    6. Proceed according to the apheresis device operator's manual.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • 3 DOSAGE FORMS AND STRENGTHS

    500 mL or 750 mL ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is a sterile solution in a polyolefin bag. Each 100 mL contains: (%w/v) Citric Acid, Monohydrate 0.8 g; Dextrose Monohydrate 2.45 g; Sodium Citrate Dihydrate 2.2 g; and Water for Injection.

  • 4 CONTRAINDICATIONS

    DO NOT INFUSE ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A DIRECTLY TO THE PATIENTS.

  • 5 WARNINGS AND PRECAUTIONS

    • Verify that the ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has been securely attached to the Anticoagulant (AC) line on the system tubing set. Use aseptic technique throughout all procedures to ensure donor safety and quality.
    • Do not reuse. Discard unused or partially used solution bags.
  • 6 ADVERSE REACTIONS

    Citrate reactions or toxicity may occur with the infusion and return of blood containing citrate anticoagulant. The recipient of the blood containing citrate should be monitored for the signs and symptoms of citrate toxicity. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by hypotension and possible cardiac arrhythmia. Citrate toxicity may occur more frequently in patients who are hypothermic, have impaired liver or renal function, or have low calcium levels because of an underlying disease.

  • 8 USE IN SPECIFIC POPULATIONS

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A has not been adequately studied in controlled clinical trials with specific populations.

  • 11 DESCRIPTION

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is designed to be metered by an apheresis device in apheresis procedures, to prevent platelet activation and coagulation as blood moves throughout the extracorporeal unit (tubing set) in an apheresis procedure.

    The solution is sterile and non-pyrogenic, and it contains no bacteriostatic or antimicrobial agents.

    The formulas of the active ingredients are provided in Table 1.

    Table 1: Active Ingredients
    IngredientsMolecular Formula Molecular Weight
    (%w/v) Citric Acid, MonohydrateC6H8O7192.12
    Dextrose MonohydrateC6H12O6 ∙ H2O198.17
    Sodium Citrate DihydrateC6H9Na3O9294.10
    Water for InjectionH2O18.00

    Each 100 mL of ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A contains: (%w/v) Citric Acid, Monohydrate 0.8 g; Dextrose Monohydrate 2.45 g; Sodium Citrate Dihydrate 2.2 g; and Water for Injection.

    The polyolefin bag is not made with natural rubber latex or PVC.

    The bag is made from a multilayered film. It contains materials that have been tested to demonstrate the suitability of the container for storing pharmaceutical solutions. The solution contact layer is an elasticized polyolefin. The bag is nontoxic and biologically inert. The bag-solution unit is a closed system and is not dependent upon entry of external air during administration. The bag is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A acts as an extracorporeal anticoagulant by binding the free calcium in the blood. Calcium is a necessary co-factor to several steps in the clotting cascade. The following ingredients are key components of the solution:

    • Citric acid for pH regulation
    • Sodium Citrate anticoagulates
    • Dextrose for isotonicity

    This solution has no pharmacological effect.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD) SOLUTION A is a clear solution supplied in sterile and non-pyrogenic polyolefin bags. The 750 mL bags are packaged 12 bags per case. The 500 mL bags are packaged 18 bags per case.

    SIZECATALOG NUMBERNDC NUMBER
    500 mL4081514537-815-50
    750 mL4081714537-817-75

    STORAGE

    Store up to 25 °C [See USP Controlled Room Temperature].
    Avoid excessive heat. Protect from freezing.

  • SPL UNCLASSIFIED SECTION

    Issued: (August 2017)

    Manufactured by
    Terumo BCT, Inc.
    Lakewood, CO 80215

  • PRINCIPAL DISPLAY PANEL - 750 mL Bag Label

    Anticoagulant Citrate Dextrose
    Solution USP (ACD) Solution A

    Catalog # 40817
    Polyolefin Bag
    750 mL

    NDC: 14537-817-75

    Sterile. Non-pyrogenic. Sterilized with Steam.

    Do not use unless the solution is clear and the
    container is intact.

    Rx Only.

    Single use container.

    Read the package insert before application.

    For use only with apheresis devices. See apheresis
    device operator's manual for complete instructions.

    Caution: Not for direct intravenous infusion.

    Recommended storage:
    Store up to 25 °C. (See USP Controlled Room
    Temperature).
    Avoid excessive heat.
    Protect from freezing.

    Each 100 mL contains:
    Dextrose Monohydrate USP
    2.45 g
    Sodium Citrate Dihydrate USP
    2.20 g
    Citric Acid Monohydrate USP
    0.80 g
    In Water for Injection USP

    Manufactured by Terumo BCT, Inc.
    10811 W. Collins Ave., Lakewood CO 80215, USA

    777967-057
    TERUMOBCT

    Lot
    Expiry Date

    PRINCIPAL DISPLAY PANEL - 750 mL Bag Label
  • PRINCIPAL DISPLAY PANEL - 500 mL Bag Label

    Anticoagulant Citrate Dextrose
    Solution USP (ACD) Solution A

    Catalog # 40815
    Polyolefin Bag
    500 mL

    NDC: 14537-815-50

    Sterile. Non-pyrogenic. Sterilized with Steam.

    Do not use unless the solution is clear and the
    container is intact.

    Rx Only.

    Single use container.

    Read the package insert before application.

    For use only with apheresis devices. See apheresis
    device operator's manual for complete instructions.

    Caution: Not for direct intravenous infusion.

    Recommended storage:
    Store up to 25 °C. (See USP Controlled Room
    Temperature).
    Avoid excessive heat.
    Protect from freezing.

    Each 100 mL contains:
    Dextrose Monohydrate USP
    2.45 g
    Sodium Citrate Dihydrate USP
    2.20 g
    Citric Acid Monohydrate USP
    0.80 g
    In Water for Injection USP

    Manufactured by Terumo BCT, Inc.
    10811 W. Collins Ave., Lakewood CO 80215, USA

    777967-540
    TERUMOBCT

    Lot
    Expiry Date

    PRINCIPAL DISPLAY PANEL - 500 mL Bag Label
  • INGREDIENTS AND APPEARANCE
    ACD   A
    citric acid monohydrate, dextrose monohydrate, and trisodium citrate dihydrate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 14537-817
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Citric Acid Monohydrate (UNII: 2968PHW8QP) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid0.8 g  in 100 mL
    Dextrose Monohydrate (UNII: LX22YL083G) (Anhydrous Dextrose - UNII:5SL0G7R0OK) Dextrose Monohydrate2.45 g  in 100 mL
    Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid2.2 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    Water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 14537-817-7512 in 1 CARTON
    1750 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDABA01022802/25/2002
    ACD   A
    citric acid monohydrate, dextrose monohydrate, and trisodium citrate dihydrate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 14537-815
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Citric Acid Monohydrate (UNII: 2968PHW8QP) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid0.8 g  in 100 mL
    Dextrose Monohydrate (UNII: LX22YL083G) (Anhydrous Dextrose - UNII:5SL0G7R0OK) Dextrose Monohydrate2.45 g  in 100 mL
    Trisodium Citrate Dihydrate (UNII: B22547B95K) (Anhydrous Citric Acid - UNII:XF417D3PSL) Anhydrous Citric Acid2.2 g  in 100 mL
    Inactive Ingredients
    Ingredient NameStrength
    Water (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 14537-815-5018 in 1 CARTON
    1500 mL in 1 BAG; Type 9: Other Type of Part 3 Combination Product (e.g., Drug/Device/Biological Product)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDABA01022802/25/2002
    Labeler - Terumo BCT, Ltd. (233649834)
    Establishment
    NameAddressID/FEIBusiness Operations
    Terumo BCT, Ltd.233649834MANUFACTURE(14537-817, 14537-815) , STERILIZE(14537-817, 14537-815) , ANALYSIS(14537-817, 14537-815) , LABEL(14537-817, 14537-815)
    • © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.